Preoperative Ketamine and Perioperative Depression
Primary Purpose
Depressive Disorder
Status
Withdrawn
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Ketamine Group
Midazolam injection
Sponsored by
About this trial
This is an interventional treatment trial for Depressive Disorder
Eligibility Criteria
Inclusion Criteria:
- Male or female patients age ≥ 65 years
- Planned lumbar surgery for degenerative disc disease or spinal stenosis involving 2 or more levels
- A life history of MDD (DSM-5 criteria) and a MADRS score ≥20
- Mini-Mental State Examination (MMSE) score ≥ 15
- MMSE is between15-26
- Ability to understand English.
Exclusion Criteria:
- MMSE < 15
- History of psychosis
- Poorly controlled hypertension
- Current opioid use before surgery
- Pre-existing aneurysmal vascular disorders
- Cocaine or other illicit drug use.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Ketamine Group
MIdazolam Group
Arm Description
Ketamine 0.5 mg/kg over 40 min via intravenous catheter.
Midazolam 0.045 mg/kg administered via intravenous catheter.
Outcomes
Primary Outcome Measures
Change in depressive symptoms in the perioperative period.
Ketamine administration changes depressive symptoms perioperatively. Measured using Depression will be measured with the Montgomery-Asberg Depression Scale (MADRS) scale. Scale ranges from 0 no depresson- 60 severe depression.
Secondary Outcome Measures
Change in depressive symptoms 1 day after surgery
Change in depressive symptoms using MADRS questionnaire measured with the Montgomery-Asberg Depression Scale scale. Scale ranges from 0 no depresson- 60 severe depression.
Safety analsysis of administration of a sub-anesthetic dose of ketamine: CADSS
To assess for the safety of administration of a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) given 1 to 3 days before surgery in the preoperative clinic (as an outpatient) by assessment of dysphoric symptoms or other complications including the need for hospitalization. The Clinician-Administered Dissociative States Scale CADSS is a 27 question survey ,19 which are completed by the subject on a scale of 0 -4 likert scale for a possible score 0- good 76 poor and 9 questions completed by the assessor (scored yes or no).
Full Information
NCT ID
NCT04220125
First Posted
January 3, 2020
Last Updated
February 2, 2023
Sponsor
Northwestern University
1. Study Identification
Unique Protocol Identification Number
NCT04220125
Brief Title
Preoperative Ketamine and Perioperative Depression
Official Title
Preoperative Ketamine as a Strategy to Decrease Perioperative Depression During the Perioperative Period: a Randomized Active Controlled Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Withdrawn
Why Stopped
No enrollment
Study Start Date
September 1, 2022 (Actual)
Primary Completion Date
February 2, 2023 (Actual)
Study Completion Date
February 2, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwestern University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Depressive symptoms, in patients with a life history of major depressive disorder (MDD), are very common in the general population, and are especially so in elderly adults undergoing surgery.Symptoms of depression at the time of surgery is associated with risk for postoperative complications.Attenuating depressive symptoms in patients undergoing surgery is thus a plausible but not adequately tested strategy for improving patient postoperative outcomes. Conventional treatment of depression takes weeks and, therefore, is not always a realistic option, particularly when surgery is urgent. Importantly, there are currently no guidelines for diagnosing and managing MDD in surgical patients. Given its association with complications including perioperative cognitive disorders such as delirium, and over longer periods of time with dementing disorders, the feasibility and efficacy of quick-acting treatments for depressive symptoms in surgical patients are direly needed. This need is particularly acute given the rising number of elderly patients undergoing surgery who are prone to depression and surgical complications.
Aim 1: To assess the feasibility of enrolling patients in a clinical trial where a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) or midazolam (0.045 mg/kg) is given 1 to 3 days before surgery in the preoperative clinic as a strategy to improve depressive symptoms during the perioperative period.
Aim 2: To obtain estimates of the variability in improvements of depressive symptoms (increase from baseline in MADRS score ≥ 2)1 day after surgery for patients given a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) 1 to 3 days before surgery compared with midazolam 0.045 mg/kg.
Aim 3: To assess for the safety and tolerability of administration of a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) given 1 to 3 days before surgery in the preoperative clinic (as an outpatient) by assessment of dysphoric symptoms or other complications including the need for hospitalization.
Hypothesis:
Aim 1: Hypothesis: Patients with preoperative depressive symptoms can be identified before surgery and successfully enrolled in a clinical trial comparing a sub-anesthetic dose of ketamine versus midazolam for improving perioperative depressive symptoms.
Aim 2: Hypothesis: Compared with midazolam, a sub-anesthetic dose of ketamine given preoperatively leads to an improvement in MADRS score ≥ 2 on day 1 after surgery.
Aim 3: Hypothesis: Compared with midazolam, a sub-anesthetic dose of ketamine is not associated with dysphoria or other complications.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depressive Disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ketamine Group
Arm Type
Experimental
Arm Description
Ketamine 0.5 mg/kg over 40 min via intravenous catheter.
Arm Title
MIdazolam Group
Arm Type
Active Comparator
Arm Description
Midazolam 0.045 mg/kg administered via intravenous catheter.
Intervention Type
Drug
Intervention Name(s)
Ketamine Group
Other Intervention Name(s)
Ketamine
Intervention Description
Ketamine intravenous administration 0.5 mg/kg over 40 minutes.
Intervention Type
Drug
Intervention Name(s)
Midazolam injection
Other Intervention Name(s)
Midazolam
Intervention Description
Midazolam intravenous administration 0.045 mg/kg IV over 40 minutes.
Primary Outcome Measure Information:
Title
Change in depressive symptoms in the perioperative period.
Description
Ketamine administration changes depressive symptoms perioperatively. Measured using Depression will be measured with the Montgomery-Asberg Depression Scale (MADRS) scale. Scale ranges from 0 no depresson- 60 severe depression.
Time Frame
3 Days before surgery to 30 days after the surgical procedure
Secondary Outcome Measure Information:
Title
Change in depressive symptoms 1 day after surgery
Description
Change in depressive symptoms using MADRS questionnaire measured with the Montgomery-Asberg Depression Scale scale. Scale ranges from 0 no depresson- 60 severe depression.
Time Frame
24 hours after surgical procedure
Title
Safety analsysis of administration of a sub-anesthetic dose of ketamine: CADSS
Description
To assess for the safety of administration of a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) given 1 to 3 days before surgery in the preoperative clinic (as an outpatient) by assessment of dysphoric symptoms or other complications including the need for hospitalization. The Clinician-Administered Dissociative States Scale CADSS is a 27 question survey ,19 which are completed by the subject on a scale of 0 -4 likert scale for a possible score 0- good 76 poor and 9 questions completed by the assessor (scored yes or no).
Time Frame
65 minutes after study drug has been infused.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female patients age ≥ 65 years
Planned lumbar surgery for degenerative disc disease or spinal stenosis involving 2 or more levels
A life history of MDD (DSM-5 criteria) and a MADRS score ≥20
Mini-Mental State Examination (MMSE) score ≥ 15
MMSE is between15-26
Ability to understand English.
Exclusion Criteria:
MMSE < 15
History of psychosis
Poorly controlled hypertension
Pre-existing aneurysmal vascular disorders
Cocaine or other illicit drug use.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Charles Hogue, MD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Preoperative Ketamine and Perioperative Depression
We'll reach out to this number within 24 hrs